Could Agios Pharmaceuticals Inc (AGIO) Go Up? The Stock Formed Bullish Wedge Up Chart Pattern

September 17, 2017 - By Stephen Andrade

Investors sentiment decreased to 1.1 in Q4 2016. Its down 0.62, from 1.72 in 2016Q3. It dived, as 23 investors sold Agios Pharmaceuticals Inc shares while 45 reduced holdings. 19 funds opened positions while 56 raised stakes. 37.23 million shares or 3.48% more from 35.97 million shares in 2016Q3 were reported.
Rhumbline Advisers has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Guggenheim Limited Com has 50,272 shares. Wells Fargo And Company Mn reported 0% stake. Tower Cap Ltd Liability Company (Trc) invested in 0.01% or 2,487 shares. Point72 Asset Management L P reported 0.03% stake. Teachers Retirement System Of The State Of Kentucky accumulated 0.02% or 45,837 shares. Luxembourg-based Artal Gru Sa has invested 0.69% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Group holds 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 671 shares. Ray Gerald L And Assoc Limited reported 33,415 shares or 0.2% of all its holdings. 11,600 were accumulated by Piermont Capital Management. Redmile Grp Limited Liability Company reported 738,451 shares. Platinum Invest Management Limited holds 0.04% or 35,800 shares in its portfolio. Us Comml Bank De holds 113 shares or 0% of its portfolio. Ecor1 Ltd Liability Corp has invested 0.32% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Ameriprise Fincl Incorporated invested 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Since March 20, 2017, it had 0 insider buys, and 7 sales for $906,379 activity. 3,000 shares were sold by Schenkein David P, worth $175,860 on Monday, April 3. Biller Scott sold $354,090 worth of stock or 6,438 shares. 2,000 Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares with value of $101,730 were sold by Cantley Lewis Clayton Jr..

The stock of Agios Pharmaceuticals Inc (AGIO) formed an up wedge with $71.74 target or 8.00 % above today’s $66.43 share price. The 5 months wedge indicates low risk for the $3.21B company. If the $71.74 price target is reached, the company will be worth $256.80 million more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock increased 1.28% or $0.84 on September 15, reaching $66.43. About 863,491 shares traded or 99.81% up from the average. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since September 17, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Analysts await Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report earnings on November, 2. They expect $-1.74 earnings per share, down 6.75 % or $0.11 from last year’s $-1.63 per share. After $-1.78 actual earnings per share reported by Agios Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -2.25 % EPS growth.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Among 15 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 11 have Buy rating, 0 Sell and 4 Hold. Therefore 73% are positive. Agios Pharmaceuticals had 35 analyst reports since July 23, 2015 according to SRatingsIntel. The company was initiated on Thursday, July 23 by Northland Capital. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Buy” rating by Cowen & Co on Tuesday, August 1. Roth Capital maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, August 5 with “Hold” rating. Leerink Swann downgraded the stock to “Market Perform” rating in Monday, December 7 report. On Wednesday, May 18 the stock rating was maintained by Credit Suisse with “Outperform”. On Friday, August 7 the stock rating was maintained by Canaccord Genuity with “Hold”. The stock has “Outperform” rating by Credit Suisse on Thursday, January 21. Suntrust Robinson maintained the stock with “Buy” rating in Wednesday, May 18 report. The stock has “Neutral” rating by TH Capital on Monday, November 9. Oppenheimer maintained the shares of AGIO in report on Tuesday, August 1 with “Buy” rating.

More news for Agios Pharmaceuticals Inc (NASDAQ:AGIO) were recently published by: Seekingalpha.com, which released: “Agios, Amigos!” on May 26, 2017. Seekingalpha.com‘s article titled: “Agios: Smooth First Mover In Cancer Metabolism” and published on August 08, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.